secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001104659-25-096047
Event type: other
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics cuts 32% of workforce, expects $520K severance costs, extends cash runway into Q2 2026
--------------------------------------------------------------------------------

- Board approved restructuring plan to focus on business development and VCN-01 clinical trials for PDAC and retinoblastoma.
- Workforce reduction of ~7 employees (32% of global workforce) implemented September 30, 2025.
- Estimated $520K in cash severance and benefits charges in Q4 2025; expects ~$2M annual compensation savings.
- Cash runway extended into Q2 2026 due to cost reductions and anticipated operating savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/0001104659-25-096047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/tm2527561d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer